Science News
from research organizations

New psoriasis drug shows potential

Date:
July 16, 2014
Source:
University of Alabama at Birmingham
Summary:
Secukinumab is a safe and effective psoriasis treatment, a new study concludes. Affecting more than 3 percent of people in the United States, psoriasis can go beyond the physical and also affect mental health.
Share:
       
FULL STORY

Randomized, phase III research from the University of Alabama at Birmingham shows that a new drug improves symptoms related to moderate to severe plaque psoriasis, a chronic skin disease of scaling and inflammation.

Affecting more than 3 percent of people in the United States, psoriasis can go beyond the physical and also affect mental health, according to the National Institute of Arthritis and Musculoskeletal and Skin Diseases.

Boni E. Elewski, M.D., professor of dermatology, is the principal investigator of the Efficacy of Response And Safety of two fixed secUkinumab REgimens in psoriasis (ERASURE) trial, one of two studies in the recent New England Journal of Medicine article "Secukinumab in Plaque Psoriasis -- Results of Two Phase 3 Trials."

"The combined results of ERASURE, along with the FIXTURE trial, are very exciting in terms of the efficacy and safety of secukinumab," Elewski, co-lead author, said.

ERASURE compared the drug to placebo, while FIXTURE compared it to placebo and another psoriasis treatment -- etanercept. Both trials assessed the efficacy, safety and tolerability of secukinumab. Together, the trials are part of the largest phase III program in moderate to severe plaque psoriasis completed to date, which involved more than 3,300 patients in more than 35 countries.

"We found that a statistically significant percentage of secukinumab-treated moderate to severe psoriasis patients achieved an up to 90 percent skin clearance after 12 weeks, and with continued treatment, a majority of these patients had maintained those results at 52 weeks," Elewski said.

Elewski says both trials confirmed earlier findings from basic research and phase II trials of secukinumab.

"These results' being published in NEJM validates the significance of the studies and will hopefully draw attention to the major unmet need of this disease," Elewski said. "If approved, having a safe and effective drug like secukinumab would be amazing, and it will greatly improve the quality of life for psoriasis patients, many of whom are dissatisfied with existing therapies."


Story Source:

The above post is reprinted from materials provided by University of Alabama at Birmingham. Note: Materials may be edited for content and length.


Journal Reference:

  1. Richard G. Langley, Boni E. Elewski, Mark Lebwohl, Kristian Reich, Christopher E.M. Griffiths, Kim Papp, Lluís Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson, Enrique Rivas, Tsen-Fang Tsai, Norman Wasel, Stephen Tyring, Thomas Salko, Isabelle Hampele, Marianne Notter, Alexander Karpov, Silvia Helou, Charis Papavassilis. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials. New England Journal of Medicine, 2014; 140710084619009 DOI: 10.1056/NEJMoa1314258

Cite This Page:

University of Alabama at Birmingham. "New psoriasis drug shows potential." ScienceDaily. ScienceDaily, 16 July 2014. <www.sciencedaily.com/releases/2014/07/140716214910.htm>.
University of Alabama at Birmingham. (2014, July 16). New psoriasis drug shows potential. ScienceDaily. Retrieved September 1, 2015 from www.sciencedaily.com/releases/2014/07/140716214910.htm
University of Alabama at Birmingham. "New psoriasis drug shows potential." ScienceDaily. www.sciencedaily.com/releases/2014/07/140716214910.htm (accessed September 1, 2015).

Share This Page: